You are here: Industry Insights > AstraZeneca

News List

Calquence significantly prolonged time patients lived without disease progression or death in previously untreated CLL pharmaceutical-business-review
December 11, 2019
AstraZeneca presented results from the interim analysis of the Phase III ELEVATE TN trial, showing that Calquence (acalabrutinib) combined with obinutuzumab or ...
AstraZeneca-Merck’s Lynparza approved in China for ovarian cancer pharmaceutical-technology
December 09, 2019
AstraZeneca and Merck (MSD) have received the National Medical Products Administration (NMPA) approval in China for Lynparza (olaparib) to treat ...
Better Asthma Care in Puskesmas Improves Disease Control and Reduces Economic Burden En-CPhI.CN
October 15, 2019
In line with Indonesia's National Health Coverage (BPJS)'s objective to strengthen government primary healthcare clinics (Puskesmas) ...
CHMP recommends AstraZeneca’s Qtrilmet for type 2 diabetes pharmaceutical-technology
September 25, 2019
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the marketing authorisation of AstraZeneca’s Qtrilmet to treat type 2 diabetes in adults.
AstraZeneca launches health innovation hub in Wuxi biospectrumasia
September 20, 2019
AstraZeneca’s Wuxi innovation story began back in 2017 with the creation of the Healthcare Internet of Things Innovation Center, established to explore innovative new treatment options and to seek out opportunities for integrating digital solutions into t
AstraZeneca amends collaboration with Ironwood for Linzess in China worldpharmanews
September 20, 2019
AstraZeneca has amended its collaboration agreement with Ironwood Pharmaceuticals, Inc. (Ironwood) in China mainland, China Hong Kong, S.A.R., China and China Macau, S.A.R., China for Linzess (linaclotide) ...
Ironwood Pharmaceuticals and AstraZeneca Amend LINZESS Collaboration in China biospectrumasia
September 19, 2019
Ironwood to receive up to $125 million, consisting of $35 million in non-contingent payments and up to $90 million in commercial milestones, in addition to tiered royalties up to 20 percent
FDA grants Fast Track designation for Farxiga in heart failure worldpharmanews
September 18, 2019
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death...
Schrödinger, AstraZeneca join hands to accelerate drug dicovery biospectrumasia
September 05, 2019
Schrödinger’s platform will be used by AstraZeneca’s medicinal and computational chemists
Tagrisso approved in China as a 1st-line treatment for EGFR-mutated non-small cell lung cancer worldpharmanews
September 05, 2019
AstraZeneca announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-line treatment for adults with locally-advanced...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page